Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2025 earnings guidance on Saturday. The company provided earnings per share (EPS) guidance of 5.450-5.650 for the period, compared to the consensus estimate of 5.540. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Wells Fargo & Company lifted their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler raised Solventum from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. Finally, The Goldman Sachs Group increased their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $80.29.

Solventum Stock Performance

NYSE:SOLV opened at $74.83 on Monday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The firm has a market cap of $12.95 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 1.94 and a beta of 0.54. The business has a 50 day moving average price of $69.36 and a 200-day moving average price of $71.55.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.15. The firm had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.02 billion. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.08 EPS. Equities research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Institutional Trading of Solventum

Large investors have recently bought and sold shares of the company. Intech Investment Management LLC lifted its stake in shares of Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after purchasing an additional 10,425 shares during the period. Woodline Partners LP grew its stake in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after purchasing an additional 3,377 shares during the period. Finally, United Services Automobile Association bought a new position in Solventum in the first quarter worth $239,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.